South Korea, widely praised around the world for its handling of the
pandemic without a full lockdown, has reported 12,602 coronavirus
cases as of Thursday midnight, with 282 deaths.
Remdesivir is designed to hinder certain viruses, including the new
coronavirus, from making copies of themselves and potentially
overwhelming the body's immune system. The drug previously failed
trials as an Ebola treatment.
South Korea's updated guidelines come after a study showed that the
cheap and widely used dexamethasone reduced deaths in very sick
COVID-19 patients. They advised doctors to take caution until a full
study is published.
"It seems appropriate to administer (dexamethasone), limited to
severe cases with acute respiratory syndrome, as the doctor monitors
the patient's condition," Kim Young-ok, director general of
pharmaceutical safety bureau at the Ministry of Food and Drug
Safety, told a briefing on Friday.
There was enough domestic supply of the dexamethasone, widely used
since the 1960s, with the production of approximately 43 million
tablets and 60 million injection ampoules a year, said Kim.
Doctors in Europe will soon be able to treat patients with the drug
after the healthcare regulator's endorsement put it on track to
become the first therapy for the disease on the continent.
[to top of second column] |
"An excessive use of dexamethasone can trigger different side effects as it
tamps down the immune system along with inflammation, possibly leading to even
cataract or glaucoma," said Dr. Song Dae-sub, professor of pharmacy at Korea
University.
Korean health authorities also advised the dropping of hydroxychloroquine after
a study found the decades-old malaria drug, which U.S. President Donald Trump
touted a possible treatment, did not provide any benefit.
There are currently no approved vaccines or treatments for the coronavirus,
which has killed more than 488,467 people globally, but about a dozen vaccines
from more than 100 candidates globally are being tested on humans.
(Reporting by Sangmi Cha; Editing by Miyoung Kim and Nick Macfie)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|